Allopurinol - NuBioPharma
Alternative Names: Allopurinal - NuBioPharma; Allopurinol oral suspension - NuBioPharmaLatest Information Update: 28 Jul 2023
At a glance
- Originator NuBioPharma
- Class Antigouts; Purines; Pyrazoles; Pyrimidinones; Skin disorder therapies; Uricosurics
- Mechanism of Action Xanthine oxidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Hyperuricaemia; Tumour lysis syndrome
Most Recent Events
- 28 Jul 2023 No recent reports of development identified for clinical-Phase-Unknown development in Hyperuricaemia in USA (PO, Suspension)
- 28 Jul 2023 No recent reports of development identified for clinical-Phase-Unknown development in Tumour lysis syndrome in USA (PO, Suspension)
- 06 Jul 2021 Allopurinol oral suspension is still in clinical trials for Hyperuricaemia and Tumour lysis syndrome (NuBioPharma website, July 2021).